Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jetrea

- PMLiVE

Novartis Access Scheme launches in Kenya

Expands affordable treatment options against chronic diseases

- PMLiVE

Lundbeck sways NICE with new Brintellix data

Final draft guidance now backs the major depressive disorder drug

National Institute for Health and Care Excellence NICE logo

NICE to speed up adoption of health technologies

Launches new Office for Market Access

National Institute for Health and Care Excellence NICE logo

NICE recommends Keytruda for advanced skin cancer

Second recommendation for drug in a week

- PMLiVE

Novartis signs $500m immuno-oncology deal

Gains access to Xoma's TGFb antibody programme

- PMLiVE

Novartis’ Cosentyx effective in psoriatic arthritis study

Further supports drugs ability to reduce progression of damage to joints

- PMLiVE

CHMP backs GSK’s asthma antibody and Novartis’ heart failure drug

Positive opinions for GSK's IL-5 antibody and Novartis' potential $5bn-a-year brand

- PMLiVE

Novartis to make 15 drugs available at $1 a month

Comes after concerns surrounding hiked drug prices and effects on public health

National Institute for Health and Care Excellence NICE logo

NICE gives nod to Gilead’s Zydelig

First class of drug to be recommended for leukaemia

- PMLiVE

National Audit Office agrees CDF is ‘unsustainable’

Says a replacement for the CDF is urgently needed

- PMLiVE

Lilly’s Cyramza not backed in draft NICE guidance

Institute says drug is not a cost-effective use of NHS resources

- PMLiVE

Pricing of Novartis’ Entresto about right, concludes ICER

Supports potential for $5bn-a-year brand 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links